

**Going beyond Commitment.**



## SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034  
UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 th SEPT 2012


PART - I		(' in lacs), except share data				Rs. in Lacs	
Sl. No.	PARTICULARS	Quarter Ended			Year to date figures		Previous Year Ended
		30/9/2012 Unaudited	30/6/2012 Un-audited	30/09/2011 Unaudited	30/09/2012 Unaudited	30/09/2011 Unaudited	31/3/2012 Audited
1	<b>Income from operations</b>						
	(a) Net sales/income from operations (Net of excise duty)	5,025.90	7,052.72	4,804.38	12,078.62	9,267.66	20,420.78
	(b) Other operating income	-	-	-	-	-	-
	<b>Total income from operations (net)</b>	<b>5,025.90</b>	<b>7,052.72</b>	<b>4,804.38</b>	<b>12,078.62</b>	<b>9,267.66</b>	<b>20,420.78</b>
2	<b>Expenses</b>						
	a) Cost of materials consumed	1,683.66	2,144.63	1,678.55	3,828.29	3,532.66	8,145.56
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(301.91)	330.84	(92.73)	28.93	(103.35)	(564.74)
	d) Employee benefits expense	562.82	651.73	594.21	1,214.55	1,065.68	2,283.03
	e) Depreciation and amortisation expense	170.05	183.23	140.02	353.28	278.74	599.79
	f) Other expenses - Manufacturing Exps	893.71	848.55	585.70	1,742.26	1,139.77	2,667.83
	- Selling Exps	83.58	100.21	83.00	183.79	131.41	216.91
	- Administrative Exps	596.52	517.42	298.03	1,113.94	578.96	1,704.57
	- R & D Exps	682.80	874.68	877.31	1,557.48	1,625.13	3,304.91
	- Provision for MTM on Forward Contracts	(314.27)	250.96	541.86	(63.31)	541.86	348.06
	<b>Total expenses</b>	<b>4,056.96</b>	<b>5,902.25</b>	<b>4,705.95</b>	<b>9,959.21</b>	<b>8,790.86</b>	<b>18,705.92</b>
3	<b>Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>968.94</b>	<b>1,150.47</b>	<b>98.43</b>	<b>2,119.41</b>	<b>476.80</b>	<b>1,714.86</b>
4	<b>Other Income</b>	<b>(39.26)</b>	<b>52.47</b>	<b>162.28</b>	<b>13.21</b>	<b>182.56</b>	<b>190.25</b>
5	<b>Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)</b>	<b>929.68</b>	<b>1,202.94</b>	<b>260.71</b>	<b>2,132.62</b>	<b>659.36</b>	<b>1,905.11</b>
6	<b>Finance costs</b>	<b>289.75</b>	<b>321.92</b>	<b>192.97</b>	<b>611.67</b>	<b>356.55</b>	<b>990.93</b>
7	<b>Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)</b>	<b>639.93</b>	<b>881.02</b>	<b>67.74</b>	<b>1,520.95</b>	<b>302.81</b>	<b>914.18</b>
8	<b>Exceptional Items</b>	-	-	-	-	-	-
9	<b>Profit/Loss from Ordinary Activities before tax (7 ± 8)</b>	<b>639.93</b>	<b>881.02</b>	<b>67.74</b>	<b>1,520.95</b>	<b>302.81</b>	<b>914.18</b>
10	<b>Tax Expenses</b>	<b>(8.96)</b>	<b>84.68</b>	<b>(188.38)</b>	<b>75.72</b>	<b>(289.40)</b>	<b>(522.06)</b>
11	<b>Net Profit/ (Loss) from Ordinary Activities after tax (9 ± 10)</b>	<b>648.89</b>	<b>796.34</b>	<b>256.12</b>	<b>1,445.23</b>	<b>592.21</b>	<b>1,436.24</b>
12	<b>Extraordinary Items (net of tax expense ` ____ Lakhs)</b>	-	-	-	-	-	-
13	<b>Net Profit (+)/Loss(-) for the period (11 ± 12)</b>	<b>648.89</b>	<b>796.34</b>	<b>256.12</b>	<b>1,445.23</b>	<b>592.21</b>	<b>1,436.24</b>
14	<b>Share of profit / (loss) of associates*</b>	-	-	-	-	-	-
15	<b>Minority interest *</b>	-	-	-	-	-	-
16	<b>Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 ± 14 ± 15) *</b>	-	-	-	-	-	-
17	<b>Paid-up equity share capital</b> (Face Value of the Share shall be indicated)	<b>1,167.32</b> Re.1.00	<b>1,167.32</b> Re.1.00	<b>1,167.32</b> Re.1.00	<b>1,167.32</b> Re.1.00	<b>1,167.32</b> Re.1.00	<b>1,167.32</b> Re.1.00
18	<b>Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year</b>	-	-	-	-	-	<b>11,584.83</b>
19.i	<b>Earning Per Share (EPS) (before extraordinary items) (of ` Rs.1/- each) (not annualised):</b>						
	a) Basic	0.56	0.68	0.22	1.24	0.51	1.23
	b) Diluted	0.56	0.68	0.22	1.24	0.51	1.23
19.ii	<b>Earning Per Share (EPS) (after extraordinary items) (of Rs.1/- each) (not annualised):</b>						
	a) Basic	0.56	0.68	0.22	1.24	0.51	1.23
	b) Diluted	0.56	0.68	0.22	1.24	0.51	1.23

PART - II		30/9/2012	30/6/2012	30/09/2011	30/09/2012	30/09/2011	31/3/2012
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>	Unaudited	Un-audited	Unaudited	Unaudited	Unaudited	Audited
1	Public share holdings - Number of shares - Percentage of Share holding	42,679,160 36.56%	42,679,160 36.56%	42,679,160 36.56%	42,679,160 36.56%	42,679,160 36.56%	42,679,160 36.56%
2	Promoters and promoter group Shareholding** a) Pledged / Encumbered - Number of shares - Percentage of Shares (as a % of the total shareholding of promoter and promoter group) - Percentage of shares (as a % of the total share capital of the company) b) Non-Encumbered - Number of shares - Percentage of Shares (as a % of the total shareholding of promoter and promoter group) - Percentage of shares (as a % of the total share capital of the company)	NIL NIL NIL 74,052,828 100.00% 63.44%	NIL NIL NIL 74,052,828 100.00% 63.44%	NIL NIL NIL 74,052,828 100.00% 63.44%	NIL NIL NIL 74,052,828 100.00% 63.44%	NIL NIL NIL 74,052,828 100.00% 63.44%	NIL NIL NIL 74,052,828 100.00% 63.44%
Particulars		3 months ended (30/09/2012)					
<b>B</b>	<b>INVESTOR COMPLAINTS</b>						
	Pending at the beginning of the quarter	0					
	Received during the quarter	20					
	Disposed of during the quarter	20					
	Remaining unresolved at the end of the quarter	0					

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED							Rs. in Lacs
PARTICULARS	Quarter Ended			Year to date figures		Year Ended	
	30/9/2012	30/6/2012	30/09/2011	30/09/2012	30/09/2011	31/3/2012	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
<b>1</b>	<b>SEGMENT REVENUE :-</b>						
a)	4,359.17	6,514.95	4,358.64	10,874.12	8,674.26	19,168.87	
b)	666.73	537.77	454.23	1,204.50	612.45	1,251.91	
c)	-	-	-	-	-	-	
	<b>5,025.90</b>	<b>7,052.72</b>	<b>4,812.87</b>	<b>12,078.62</b>	<b>9,286.71</b>	<b>20,420.78</b>	
<b>2</b>	<b>SEGMENT RESULTS :-</b>						
	Profit/(Loss) before tax and interest:						
a)	1,417.44	2,494.37	1,512.59	3,911.81	2,839.90	6,507.91	
b)	406.29	231.20	279.78	637.49	348.33	531.83	
c)	(682.80)	(874.68)	(877.31)	(1,557.48)	(1,625.13)	(3,304.91)	
	<b>1,140.93</b>	<b>1,850.89</b>	<b>915.06</b>	<b>2,991.82</b>	<b>1,563.10</b>	<b>3,734.83</b>	
Less: i)	261.41	298.14	192.97	559.55	356.55	888.50	
ii)	239.59	671.73	654.35	911.32	903.74	1,932.15	
	<b>639.93</b>	<b>881.02</b>	<b>67.74</b>	<b>1,520.95</b>	<b>302.81</b>	<b>914.18</b>	
<b>3</b>	<b>CAPITAL EMPLOYED</b>						
	(Segment Assets - Segment Liabilities)						
a)	11,544.66	11,483.10	12,566.39	11,544.66	12,566.39	10,704.10	
b)	3,137.56	3,131.68	381.73	3,137.56	381.73	3,298.34	
c)	2,513.05	2,525.28	3,438.29	2,513.05	3,438.29	2,228.26	
d)	4,613.35	1,564.05	3,569.93	4,613.35	3,569.93	2,023.90	
	<b>21,808.62</b>	<b>18,704.11</b>	<b>19,956.34</b>	<b>21,808.62</b>	<b>19,956.34</b>	<b>18,254.60</b>	

- Notes: 1) The above un-audited results were approved and taken on record at the Board of Directors' meeting held on 14th Nov '12  
2) Previous years figures have been regrouped / reclassified whenever necessary.  
3) The limited review has been completed by the Statutory Auditors.  
4) Provision for MTM Losses/gains pertaining to Forward Contracts entered for covering the future receivables in USD.  
5) Suven Nishta pharma pvt ltd, the 100% subsidiary, has been merged wef 1 st Jan 2012 and accordingly the results have been prepared. Hence the current year's figures are not comparable with the previous year figures.

For SUVEN LIFE SCIENCES LTD

  
VENKAT JASTI

Chairman & CEO

Place : Hyderabad  
Date : 14 th Nov'2012

**We Deliver**